基本信息
views: 609
Career Trajectory
Bio
Dr. Shepherd's contribution to the development and conduct of clinical trials is recognized internationally. She was the President of the International Association for the Study of Lung Cancer from 2005-2007. She was a member of the US National Institutes of Health Concept Evaluation Panel for Lung Cancer clinical trials. This body of CTEP (the Cancer Treatment Evaluation Program of the US NCI) was responsible for evaluating and approving all multi-center lung cancer clinical research studies submitted by the large US cooperative groups.
Currently, she sits on the Board of Directors of the American Society of Clinical Oncology and the European Organization for Research and Treatment of Cancer. She also Chairs the European Organization for Research and Treatment of Cancer Protocol Review committee. Dr Shepherd has served as Chair of the American Society of Clinical Oncology Membership and Publications Committees.
Dr. Shepherd has been instrumental in the design and conduct of research studies evaluating the new targeted agents and anti-angiogenesis agents in lung cancer. She has also undertaken translational research studies in this field. Most recently she has developed several large international randomized trials for some of the novel anti-cancer agents that are directed against the epidermal growth factor receptor and other molecular targets.
Currently, she sits on the Board of Directors of the American Society of Clinical Oncology and the European Organization for Research and Treatment of Cancer. She also Chairs the European Organization for Research and Treatment of Cancer Protocol Review committee. Dr Shepherd has served as Chair of the American Society of Clinical Oncology Membership and Publications Committees.
Dr. Shepherd has been instrumental in the design and conduct of research studies evaluating the new targeted agents and anti-angiogenesis agents in lung cancer. She has also undertaken translational research studies in this field. Most recently she has developed several large international randomized trials for some of the novel anti-cancer agents that are directed against the epidermal growth factor receptor and other molecular targets.
Research Interests
Papers共 869 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Targeted Oncologyno. 2 (2024): 1-4
Journal of Thoracic Oncology (2024)
C.K. Lee,Y. Cheng,K. Laktionov,S-W. Kim, T. Kato, J. Wang, P. Mitchell, V. Bermudez,S. Kuyama, J.Y. Tan Chun Bing, J.E. Cundom, G.D.J. Pinto,
ESMO Open (2024)
C. Theriau, J. Feng,L. Eng,F.A. Shepherd, M. De Carolis,V. Glenns, S. Kulkarni,R. Vandermeer, U. Zurawska-Fortin,D. Hao,L. Le, I. Wozniczka,
ESMO Open (2024)
crossref(2024)
Sam Khan, Beatriz Jimenez,Katrina Hueniken, Tianzhichao Hou,Devalben Patel,Tracy Stockley,Ming-Sound Tsao,Alona Zer,Mor Moskovitz, Yehuda Rosenberg,Penelope Ann Bradbury,Lawson Eng,
Journal of Clinical Oncologyno. 16_suppl (2024): 12092-12092
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancerno. 6 (2024): 928-940
The Lancet. Public healthno. 9 (2023): e691-e700
R.S. Herbst,Y.-L. Wu,C. Grohe,T. John,M. Majem, J. Wang, T. Kato,J.W. Goldman, S.-W. Kim,C.-J. Yu,H.V. Vu,G. Mukhametshina,
Journal of Thoracic Oncologyno. 3 (2023): e4-E4
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn